Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

Adenosine A(2A) receptor (A(2A)R) agonists have been shown to decrease tissue inflammation induced by hypoxia/reoxygenation in mice with sickle cell disease (SCD). The key mediator of the A(2A)R agonist’s anti-inflammatory effects is a minor lymphocyte subset, invariant natural killer T (iNKT) cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Field, Joshua J., Majerus, Elaine, Gordeuk, Victor R., Gowhari, Michel, Hoppe, Carolyn, Heeney, Matthew M., Achebe, Maureen, George, Alex, Chu, Hillary, Sheehan, Brian, Puligandla, Maneka, Neuberg, Donna, Lin, Gene, Linden, Joel, Nathan, David G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728341/
https://ncbi.nlm.nih.gov/pubmed/29296811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009613
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados